Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MD-110 Phase 3 Study in Breast Cancer Patients Receiving TC Chemotherapy
jRCT2080225134Phase 3Completed
- Sponsor
- Mochida Pharmaceutical Co., Ltd.
- Start
- Mar 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of pegfilgrastim in chemotherapy-induced neutropenia (CIN) and breast cancer (2 arms), sponsored by Mochida Pharmaceutical Co., Ltd. Primary endpoint: Efficacy against chemotherapy-induced neutropenia. Started Mar 2020; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
chemotherapy-induced neutropenia (CIN)breast cancer
Beyond the preview
Go deeper on jRCT2080225134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225134.